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SUMMARY. Hydroquinone (HQ) is a drug reported to possess manifold biological activities. HQ is highly
unstable into various topical vehicles, presenting low topical bioavailability and a relevant level of toxicity.
The Pluronic® Lecithin Organogel (PLOme) is a phospholipidic microemulsion designed for transdermal
purposes. The aim of this work was therefore to incorporate HQ into PLOme. We evaluated the stability,
the kinetic profile and the antimicrobial activity of HQ- incorporated PLOme. No relevant pH variation
was observed. Long-term stability test showed an HQ degradation which led to a short shelf life. HQ per-
meation rate obtained was lower from PLOme than from a gel matrix. Free and PLOme-encapsulated hy-
droquinone showed to have a great in vitro inhibitory potential against of S. aureus strains. The encapsula-
tion of HQ due its unstable characteristics could be an alternative to optimize its therapeutic usage, and so
further investigation is required on this pharmaceutical form before commercialization.
